Asthma Clinical Trial
Official title:
Using the Telephone to Improve Care in Childhood Asthma
Asthma is the most common chronic disease of childhood and a major cause of morbidity in the
United States. If asthma symptoms are controlled, a child with asthma can stay well and lead
a normal life. Daily use of inhaled steroids controls symptoms and reduces morbidity and
emergent health care utilization in children with persistent asthma, and is safe for
long-term use. However, inhaled steroids are underused in community asthma care.
The Telephone Asthma Program (TAP) is a series of brief, telephone calls with a trained
coach to help the parent manage the child's asthma care. The coach will teach
self-management skills, help the parent to use the child's asthma medicines effectively,
provide support and remind the parent to go for follow-up care with the pediatrician. We
hypothesized that the Telephone Asthma Program will reduce the incidence of acute
exacerbations of asthma that require emergent care, improve the quality of life of children
with asthma and their parents, and increase the daily use of inhaled steroids in children
with persistent asthma. We evaluated the Telephone Asthma Program in a randomized controlled
trial involving 362 children aged 5 to 12 years old cared for by community pediatricians.
Eligible children were randomized to the TAP program or usual care by their pediatrician.
| Status | Completed |
| Enrollment | 362 |
| Est. completion date | June 2007 |
| Est. primary completion date | January 2006 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 5 Years to 12 Years |
| Eligibility |
Inclusion Criteria: - Physician diagnosis of asthma for at least a year - At least one acute exacerbation of asthma in past 12 months that required a visit to the emergency department, hospitalization or an unscheduled office visit for acute care and/or a course of oral steroids. - Taking daily controller medications or symptoms consistent with persistent asthma Exclusion Criteria: - No phone - Unable to speak English - Child has another disease that requires regular monitoring by pediatrician - A sibling is already enrolled in the study - Child's primary asthma provider is an asthma specialist |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
| Country | Name | City | State |
|---|---|---|---|
| United States | Washington University School of Medicine | St Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Agency for Healthcare Research and Quality (AHRQ) |
United States,
Garbutt J, Bloomberg G, Banister C, Sterkel R, Epstein J, Bruns J, Swerczek L, Wells S. What constitutes maintenance asthma care? The pediatrician's perspective. Ambul Pediatr. 2007 Jul-Aug;7(4):308-12. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Parental asthma-related quality of life | one year | No | |
| Primary | Urgent care events for asthma | One year | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|